2025-01-27 – Press Releases – www.prnewswire.com
ATLANTA, Jan. 27, 2025 /PRNewswire/ — Cambium Oncology is pleased to share that their lead drug candidate, ANT308, recently demonstrated outstanding single-agent efficacy and safety in preclinical studies. The drug is mutation-agnostic, and the company observes no toxicity-limiting…
